Madrigal Pharma's Q2 sales surge on Rezdiffra demand
Overview
Madrigal Q2 2025 net sales rise to $212.8 mln from $14.6 mln year-ago, driven by demand for NASH treatment Rezdiffra
Co secures new U.S. patent for Rezdiffra, extending protection to 2045
Madrigal enters global licensing agreement for oral GLP-1 candidate
Result Drivers
REZDIFFRA DEMAND - Strong demand for Rezdiffra drove Q2 2025 net sales to $212.8 mln, up from $14.6 mln in the prior year period, per CEO Bill Sibold
PATENT EXTENSION - New U.S. patent extends Rezdiffra's protection to 2045, securing long-term market position, according to CEO Bill Sibold
PIPELINE ADVANCEMENT - Madrigal announced a global licensing agreement for an oral GLP-1 development candidate, SYH2086, expected to enter clinical trials in H1 2026
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Product Revenue |
| $212.80 mln |
|
Q2 EPS |
| -$1.9 |
|
Q2 Net Income |
| -$42.28 mln |
|
Q2 Operating Expenses |
| $260 mln |
|
Q2 Operating Income |
| -$47.20 mln |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 15 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Madrigal Pharmaceuticals Inc is $417.50, about 25.2% above its August 4 closing price of $312.11
Press Release: ID:nGNX4qR7vp
